Form 4 for RANI Rani Therapeutics Holdings, Inc.
Accepted 2022-03-24 00:00:00 ET · period of report 2022-03-22 · accession 0001209191-22-021022 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| D | 2022-03-24 | 2022-03-22 | RANI | Imran Talat | CEO, Dir | A - Grant | $0.00 | +86.6K | 98.9K | +702% | $0 |
| D | 2022-03-24 | 2022-03-22 | RANI | Imran Talat | CEO, Dir | A - Grant | $0.00 | +263.4K | 263.4K | New | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Class A Common Stock | 2022-03-22 | A | A | 86,600 | $0.00 | 98,943 | D | — | — | |
| 2 | Derivative | Stock Option (Right to Buy) | 2022-03-22 | A | A | 263,400 | $0.00 | 263,400 | D | $13.21 · — to 2032-03-21 | 263,400 Class A Common Stock | (F2) The shares subject to the option vest as follows: 1/48th of the shares subject to the option vest monthly over four years from March 22, 2022. |